Retatrutide research: RETA, Phase 3 trials and evidence limits
Retatrutide, also known as LY3437943 or informally RETA, is an investigational molecule studied for activity at GIP, GLP-1 and glucagon receptors. “GLP-3” is an informal catalog label, not the name of a third GLP receptor or an approval category.
RETA is a search abbreviation. Retatrutide is the full molecule name; LY3437943 is its development identifier. Keep these names connected on one reference page instead of treating each Hebrew spelling as a different product.
Retatrutide name and identity cross-reference
| Name on a page | What it means | What it does not verify |
|---|---|---|
| Retatrutide / LY3437943 | The molecule and its development identifier | A commercial vial’s identity, quantity or provenance |
| RETA / רטא / רטטרוטייד / רטטרוטיד | Abbreviations and Hebrew transliterations used in searches | A separate medicine, batch or quality grade |
| GLP-3 / L∅C 3R | Informal catalog or brand labels in this context | A third GLP receptor or regulatory approval |
Common questions
Is RETA the same name as retatrutide?
RETA is commonly used as shorthand for retatrutide, but a short name does not authenticate material. Use the full chemical identity and match the sample and lot to the original laboratory record.
Does a retatrutide clinical trial validate a catalog vial?
No. A trial concerns its defined study product, participants and protocol. A supplier’s vial needs its own identity and lot documentation; a medicine-status question must be checked separately against the exact product record.
The 2026 update: Phase 3 is now published
Retatrutide / LY3437943 is studied as a GIP, GLP-1 and glucagon receptor agonist. The peer-reviewed TRIUMPH-1 report appeared September 29, 2026, after the earlier Phase 2 report. Phase 3 publication is not marketing authorization and does not authenticate a separately supplied vial.
For the actual participant counts, follow-up, weight endpoints and estimand differences, use our maintained clinical-trial comparison linked below. Keeping the full results in one comparison avoids inconsistent duplicated tables. For רטטרוטייד, רטטרוטיד or רטא searches, retain the English name to distinguish the molecule from a shorthand or storefront code.
Retatrutide in Israel: read the official trial record
The Israeli Ministry of Health record MOH_2024-03-07_013284 describes protocol J1I-MC-GZBO, a randomized, double-blind, placebo-controlled Phase 3 study of cardiovascular and kidney outcomes. The sponsor identifies this protocol as TRIUMPH-Outcomes, NCT06383390. It is a separate research question from the weight-change trials summarized in our comparison.
Checked October 22, 2026: the Israeli record displayed recruiting and identified the study product as not registered. These are dated registry fields, not a guarantee of an open place at a particular center or a complete eligibility assessment. A trial record is not a published outcome, marketing authorization or authentication of a supplier vial. Locked Aminos is not represented here as a trial site, sponsor or enrollment service; use the official record for current research information.
Primary sources and verification records

Names identify the topic, not the batch
Hebrew searches may use רטטרוטייד, רטטרוטיד, רטאטרוטייד, רטרוטייד, רטא or רטה. Keep these as spelling aids on one reference page. When matching laboratory records, use the complete scientific name, chemical form, sample and lot. The L∅C 3R brand code does not replace that identification.
Read the trial before the headline
The 2023 peer-reviewed phase 2 trial investigated retatrutide in adults with obesity. It reported clinical outcomes for a defined study product, protocol and population. Its results are not a quality certificate for a commercial vial. Subsequent development should be checked against dated primary publications and the developer’s current statements, not an undated supplier summary.
Investigational status is not a purchasing instruction
Lilly’s September 2026 communication describes retatrutide as investigational and available legally only through its clinical trials. This reference does not represent any catalog material as Lilly’s trial product, an approved medicine or a route to clinical participation. The Israeli regulatory status of a specific medicine must be checked with the relevant authority.
How to compare the metabolic compounds
Semaglutide, tirzepatide and retatrutide have different receptor profiles and development histories. Counting receptor targets does not rank safety or prove superior outcomes. Comparisons require the same outcome definition, follow-up and population, preferably a suitable direct trial. None of these comparisons supplies a self-treatment plan.
Sources and review scope
- NEJM: retatrutide phase 2 trial (2023)
- Lilly: EASD development update (September 2026)
- Israel Ministry of Health: drug database
Sources explain terminology and evidence limits. They are not commercial endorsements or approvals of catalog products. Check the original source for updates.
Catalog identity and documentation
These links identify laboratory materials, not treatments or clinical-trial products.
